Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-11-09
2009-10-20
Angell, J. E (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07605250
ABSTRACT:
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
REFERENCES:
patent: 6001992 (1999-12-01), Ackermann
patent: 6111086 (2000-08-01), Scaringe
patent: 6172216 (2001-01-01), Bennett et al.
patent: 6291642 (2001-09-01), Weinstein
patent: 6506559 (2003-01-01), Fire et al.
patent: 6965025 (2005-11-01), Gaarde et al.
patent: 6994979 (2006-02-01), Reed
patent: 7022831 (2006-04-01), Reed
patent: 7022837 (2006-04-01), Harding
patent: 7157570 (2007-01-01), Yen
patent: 2002/0081578 (2002-06-01), Plowman
patent: 2002/0086321 (2002-07-01), Craig
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0150945 (2002-10-01), Finney et al.
patent: 2003/0087259 (2003-05-01), Clancy et al.
patent: 2003/0105051 (2003-06-01), McSwiggen
patent: 2003/0143732 (2003-07-01), Fosnaugh
patent: 2003/0157030 (2003-08-01), Davis et al.
patent: 2003/0228597 (2003-12-01), Cowsert
patent: 2004/0029275 (2004-02-01), Brown et al.
patent: 2004/0054155 (2004-03-01), Woolf et al.
patent: 2004/0063654 (2004-04-01), Davis et al.
patent: 2004/0101857 (2004-05-01), Ward
patent: 2004/0180357 (2004-09-01), Reich et al.
patent: 2004/0204380 (2004-10-01), Ackermann
patent: 2004/0219671 (2004-11-01), McSwiggen
patent: 2004/0248296 (2004-12-01), Beresford
patent: 2004/0248299 (2004-12-01), Jayasena et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0048529 (2005-03-01), McSwiggen
patent: 2005/0107328 (2005-05-01), Wyatt
patent: 2005/0130181 (2005-06-01), McSwiggen
patent: 2005/0176025 (2005-08-01), McSwiggen et al.
patent: 2005/0181382 (2005-08-01), Zamore et al.
patent: 2005/0186586 (2005-08-01), Zamore et al.
patent: 2005/0227935 (2005-10-01), McSwiggen
patent: 2005/0239731 (2005-10-01), McSwiggen et al.
patent: 2005/0245475 (2005-11-01), Khvorova
patent: 2006/0286575 (2006-12-01), Farrell
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 2007/0254850 (2007-11-01), Lieberman
patent: WO9800532 (1998-01-01), None
patent: WO0020645 (2000-04-01), None
patent: WO0021559 (2000-12-01), None
patent: WO0076497 (2000-12-01), None
patent: WO 0244321 (2002-06-01), None
patent: WO03035869 (2003-05-01), None
patent: WO03035870 (2003-05-01), None
patent: WO03070897 (2003-08-01), None
patent: WO03070969 (2003-08-01), None
patent: WO03646625 (2003-08-01), None
patent: WO03072704 (2003-09-01), None
patent: WO2004031237 (2004-04-01), None
patent: WO2004046324 (2004-06-01), None
patent: WO2004048511 (2004-06-01), None
patent: WO2004090105 (2004-10-01), None
patent: WO2005001043 (2005-01-01), None
patent: WO2005078095 (2005-08-01), None
patent: WO2005089224 (2005-09-01), None
patent: WO2005117991 (2005-12-01), None
patent: WO2006015389 (2006-02-01), None
patent: WO2006110813 (2006-10-01), None
Levenkova, Gene specific siRNA selector, Bioinofrmatics vol. 20, pp. 430-432 (2004).
Lindgren, et al. (2002) Contribution of Known and Unknown Susceptibility Genes to Early-Onset Diabetes in Scandinavia, Diabetes vol. 51, 1609-1617.
Lu, et al., The Human AQP4 gene: Definition of the locus encoding two water channel polypeptides in brain, Proc. Natl Acad. Sci vol. 93, pp. 10908-10912 (Oct. 1996).
Marathi, RAD1, a Human Structural Homolog of the Schizosaccharomyces pombe RAD1 Cell Cycle Checkpoint Gene, Genomcs 54, 344-347 (1998).
Miller, V M et al., “Allele-specific silencing of dominant disease genes” Proceedings of the National Acadamy of Sciences of USA, vol. 100, No. 12, Jun. 10, 2003, pp. 7195-7200 , XP002276730.
Miyagashi et al. (2003) Comparison of the Suppressive Effects of Antisense Oligonucleotides and siRNAs Directed Against the Same Targets in Mammalian Cells. Antisense and Nucleic Acid Drug Development 13:1-7.
Murphy, et al. (2000) Synucleins are Developmentally Expressed, and Alpha-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons. The Journal of Neuroscience, vol. 20(9):3214-20.
Naito, siDirect: highly effective, target specific siRNA design software for mammalian RNA interference, Nucleic Acids Research vol. 32, W124-129 (2004).
NCBI Nucleotide Result for NM-002609, http://www.ncbi.nlm.nih.gov/sites/entrez, accessed on Jul. 14, 2008.
NCBI Sequence Viewer v2.0 for NM-004438, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi? db=nuccore&id=45439363, accessed on Jul. 3, 2008.
Olie et al, A Novel Antisense Oligonucleotide Targeting Survivin Expression Induces Apoptosis and Sensitizes Lung Cancer Cells to Chemotherapy, Cancer Research 2000, vol. 60: pp. 2805-2809.
Oishi, et al., Identification and Characterization of PKN Beta, a Novel lsoform of Protein Kinase PKN: Expression and Arachiodonic Acid Dependency Are Different from those of PKN alpha, 1999 Biochemical and Biophysical Research Communication, 261, pp. 808-814.
Pan, et al. (2005) Calmodulin-dependent protein kinase IV regulates nuclear export of Cabin1 during T-cell activation, The EMBO Journal, 24, 2104-2113.
Promega siRNA Target Designer—Version 1.1, http:///www.promega.com/siRNADesigner/program/default.asp. (2003).
Promega siRNA Target Designer—Version 1.51, http:///www.promega.com/siRNADesigner/program/default.asp. Accessed Jun. 24, 2008.
Rabert et al. (1998) A Tetrodextrin-Resistant Voltage-gated Sodium Channel from Human Dorsal Root Ganglia, hPN3/SCN10A. Pain, 78, pp. 107-114.
Ross, et al. (2001) Inhibition of Kirsten-ras Expression in Human Colorectal Cancer Using Rationally Selected Kirsten-ras Antisense Oligonucleotides, Molecular Cancer Therapeutics vol. 1, 29-41.
Semizarov, Specificity of short interfereing RNA determined through gene expression signatures, Proceedings of the National Acadamy of Sciences USA vol. 100, pp. 6347-6352 (2003).
Shi et al. (2001) Gremlin negatively Modulates BMP-4 Induction of Embryonic Mouse Lung Branching Morphogenesis. Am J Physiol Lung Cell Mol Physiol, 280, pp. L1030-L1039.
siDesign Center for “gene name: src,” http://www.dharmacon.com/DesignCenter/DesignCenterPage.aspx, accessed on May 13, 2008.
siRNA Converter, http://web.archive.org/web/20020101-20021231re—/http://www.ambion.com/techlib/misc/ siRNA—finder.html. Accessed Mar. 6, 2008. (siRNA Target Finder).
siRNA Design for RNA Interference (RNAi) Experiments, http://web.archive.org/ web/20010101000000-20021231235959/http://www.ambion.com/techlib/misc/siRNA—design.html. Accessed on Mar. 6, 2008.
Sorensen, et al. (2003) Gene Silencing by Systemic Delivery of Synthetic siRNAs in Adult Mice, J. Mol. Biol. 327, 761-766.
Tan et al. (2006) Functional Cooperation Between FACT and MCM Helicase Facilitates Initiation of Chromatin DNA Replication. The EMBO Journal, vol. 25, pp. 3975-3985.
Truss, HuSide—the Human siRNA database: an open access database for published functional siRNA sequences and technical details of efficient transfer into recipient cells, Nucleic Acids Research vol. 33, pp. D108-D111 (2005).
Tsuji, et al. (2006) Essential Role of Phosphoorylation of MCM2 by Cdc7/Dbf4 in the Initiation of DNA Replication in Mammalian Cells. Molecular Biology of the Cell, vol. 17, pp. 4459-4472.
Tuschl, et al. (2001) the siRNA User Guide. Max Planck Institute for Biophysical Chemistry, pp. 1, 3 and 5, http:// www.mpibpc.gwdg.de/abteilungen/100/105/siRNAuserguide.pdf.
Tuschl, Expanding small RNA interference (May 2002), Nature Biotechnology, vol. 20, pp. 446-448.
Tuschl et al. (2003) the siRNA User Guide. 6 pages.
Vankayalapati, et al. (2003) Targeting Aurora2 Kinase in Oncogenesis: A Structural Bioinformatics Approach to Target Validation and Rational Drug Design. Molecular Cancer Therapeutics, v.2:283:94.
Vickers, Efficient Reduction of Target RNAs by Small lnterfereing RNA and Rnase H-dependent Antisense Agents, J. Biol. Chem. vol. 278, No. 9, 7108-7118 (2003).
Walton, et al. (1999) Prediction of Antisense Oligonucleotide Binding Affinity to a Structured RNA Targ
Khvorova Anastasia
Leake Devin
Marshall William
Read Steven
Reynolds Angela
Angell J. E
Dharmacon, Inc.
Kalow & Springut LLP
Locke, Esq. Scott D.
LandOfFree
siRNA targeting cAMP-specific phosphodiesterase 4D does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with siRNA targeting cAMP-specific phosphodiesterase 4D, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and siRNA targeting cAMP-specific phosphodiesterase 4D will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4060304